Published in Transl Neurodegener on July 10, 2017
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology (2009) 3.64
Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol (2009) 3.49
The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol (2013) 1.52
Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Investig Drugs (2008) 1.36
Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med (2012) 1.28
Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid Med Cell Longev (2011) 1.08
Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet (2013) 1.05
Target engagement and drug residence time can be observed in living cells with BRET. Nat Commun (2015) 1.01
Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet (2012) 1.00
Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des (2009) 0.99
Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp Neurol (2012) 0.98
Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue? Neuropharmacology (2014) 0.95
HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One (2012) 0.94
Loss of HDAC5 impairs memory function: implications for Alzheimer's disease. J Alzheimers Dis (2013) 0.93
Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. J Pharmacol Toxicol Methods (2012) 0.93
From single target to multitarget/network therapeutics in Alzheimer's therapy. Pharmaceuticals (Basel) (2014) 0.92
Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice. J Alzheimers Dis (2014) 0.92
Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue. Neuropsychopharmacology (2015) 0.91
HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models. J Clin Invest (2015) 0.88
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. J Neuropathol Exp Neurol (2013) 0.87
Brain plasticity, memory and neurological disorders: an epigenetic perspective. Neuroreport (2010) 0.85
Liquiritigenin inhibits Abeta(25-35)-induced neurotoxicity and secretion of Abeta(1-40) in rat hippocampal neurons. Acta Pharmacol Sin (2009) 0.85
The Aβ-clearance protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain. J Neurochem (2014) 0.85
The Role of Oxidative Stress-Induced Epigenetic Alterations in Amyloid- β Production in Alzheimer's Disease. Oxid Med Cell Longev (2015) 0.84
Inhibition of Histone Deacetylase 3 Restores Amyloid-β Oligomer-Induced Plasticity Deficit in Hippocampal CA1 Pyramidal Neurons. J Alzheimers Dis (2016) 0.83
Epigenetic drugs in Alzheimer's disease. Biomol Concepts (2013) 0.82
The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity. PLoS One (2014) 0.81
Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease. Clin Epigenetics (2015) 0.80
Co-location of HDAC2 and insulin signaling components in the adult mouse hippocampus. Cell Mol Neurobiol (2012) 0.80
A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice. Neuropsychopharmacology (2016) 0.80
Histone Acetylation Modifiers in the Pathogenesis of Alzheimer's Disease. Front Cell Neurosci (2015) 0.80
A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Increases Dendritic Spine Density via RasGRF1/ERK Pathway. J Alzheimers Dis (2016) 0.79
Age-dependent effects of valproic acid in Alzheimer's disease (AD) mice are associated with nerve growth factor (NGF) regulation. Neuroscience (2014) 0.79
Neurogenesis-based epigenetic therapeutics for Alzheimer's disease (Review). Mol Med Rep (2016) 0.77
Medicinal chemistry insights into novel HDAC inhibitors: An updated patent review (2012-2016). Recent Pat Anticancer Drug Discov (2016) 0.77
Post-occlusion administration of sodium butyrate attenuates cognitive impairment in a rat model of chronic cerebral hypoperfusion. Pharmacol Biochem Behav (2015) 0.76